Morgan Stanley reiterated their overweight rating on shares of Galapagos NV (NASDAQ:GLPG) in a report released on Thursday morning. They currently have a $92.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. BTIG Research restated a buy rating and issued a $98.00 price objective on shares of Galapagos NV in a research report on Wednesday, July 26th. Zacks Investment Research upgraded shares of Galapagos NV from a hold rating to a buy rating and set a $86.00 price objective for the company in a research report on Friday, July 14th. Instinet restated a buy rating and issued a $108.00 price objective (down previously from $121.00) on shares of Galapagos NV in a research report on Thursday, June 22nd. Nomura reduced their price objective on shares of Galapagos NV from $108.00 to $121.00 and set a buy rating for the company in a research report on Thursday, June 22nd. Finally, Cowen and Company restated a buy rating on shares of Galapagos NV in a research report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $96.14.

Shares of Galapagos NV (GLPG) traded up 3.183% during trading on Thursday, hitting $86.395. The stock had a trading volume of 141,352 shares. Galapagos NV has a 12-month low of $52.50 and a 12-month high of $94.88.

COPYRIGHT VIOLATION NOTICE: “Galapagos NV (GLPG) Rating Reiterated by Morgan Stanley” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/14/galapagos-nv-glpg-rating-reiterated-by-morgan-stanley.html.

Several large investors have recently bought and sold shares of GLPG. Bain Capital Public Equity Management LLC increased its stake in Galapagos NV by 30.3% in the second quarter. Bain Capital Public Equity Management LLC now owns 71,136 shares of the biotechnology company’s stock worth $5,443,000 after buying an additional 16,536 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Galapagos NV during the second quarter worth about $237,000. Citadel Advisors LLC increased its stake in Galapagos NV by 302.0% in the second quarter. Citadel Advisors LLC now owns 11,155 shares of the biotechnology company’s stock worth $854,000 after buying an additional 8,380 shares during the last quarter. Renaissance Technologies LLC increased its stake in Galapagos NV by 49.5% in the second quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock worth $35,605,000 after buying an additional 154,100 shares during the last quarter. Finally, Advisor Group Inc. increased its stake in Galapagos NV by 233.7% in the second quarter. Advisor Group Inc. now owns 3,090 shares of the biotechnology company’s stock worth $236,000 after buying an additional 2,164 shares during the last quarter. Institutional investors own 20.73% of the company’s stock.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.